Skip to main content
SpringerLink
Log in

Methylnaltrexone

MNTX

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Wyeth Pharmaceuticals, Progenics Pharmaceuticals Inc. Wyeth and Progenics Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Methylnaltrexone; Methylnaltrexone in Late-Stage Clinical Development for Opioid-Induced Constipation and Post-Operative Bowel Dys-function. Media Release: 23 Dec 2005. Available from URL: http://www.wyeth.com

    Google Scholar 

  2. Progenics Pharmaceuticals Inc. Progenics Acquires Methylnaltrexone Rights from Licensors and Plans to File Shelf Registrations. Media Release: 23 Dec 2005. Available from URL: http://www.progenics.com

    Google Scholar 

  3. Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock. Media Release: 1 Apr 2005. Available from URL: http://www.p-rogenics.com

  4. Progenics Pharmaceuticals Inc. Progenics Announces Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation; All Primary and Secondary Efficacy Endpoints Were Highly Statistically Significant. Media Release: 15 Feb 2006. Available from URL: http://www.progenics.com

    Google Scholar 

  5. Progenics Pharmaceuticals Inc. Progenics Initiates Second Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation. Media Release: 13 Jan 2004. Available from URL: http://www.progenics.com

    Google Scholar 

  6. Progenics Pharmaceuticals Inc. Progenics Achieves Enrollment Target in Second Pivotal Phase 3 Clinical Trial of Methylnal-trexone for Opioid-Induced Constipation. Media Release: 30 Sep 2005. Available from URL: http://www.progenics.com

    Google Scholar 

  7. Progenics Pharmaceuticals Inc. CORRECTING and REPLACING Progenics Announces Positive Top-Line Results from Pivotal Phase 3 Clinical Trial of methylnaltrexone in Opioid-Induced Constipation. Media Release: 10 Mar 2005. Available from URL: http://www.progenics.com

    Google Scholar 

  8. Progenics Pharmaceuticals Inc. Progenics Achieves Enrollment Target in Pivotal Phase 3 Clinical Trial of Methylnaltrexone for Opioid-Induced Constipation. Media Release: 3 Dec 2004. Available from URL: http://www.progenics.com

  9. Wyeth Pharmaceuticals, Progenics Pharmaceuticals. Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus. Media Release: 17 Jul 2006. Available from URL: http://www.wy-eth.com

    Google Scholar 

  10. Progenics Pharmaceuticals Inc. Progenics Announces Positive Top-Line Results from Phase 2 Clinical Trial of methylnaltrex-one in Post-Operative Bowel Dysfunction. Media Release: 20 Jan 2005. Available from URL: http://www.progenics.com

    Google Scholar 

  11. Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Successfully Completes Two, Phase 1 Clinical Studies of Oral Methylnaltrexone. Media Release: 25 May 2004. Available from URL: http://www.progenics.com

    Google Scholar 

  12. Progenics Pharmaceuticals Inc. Progenics Initiates Methylnaltrexone Phase-3 Clinical Program for Opioid-Induced Constipation; Positive Phase-2 Trial in Hospice Patients Provides Basis for Pivotal Study. Media Release: 20 Dec 2002. Available from URL: http://www.progenics.com

    Google Scholar 

  13. Progenics Pharmaceuticals Inc. Progenics Reports Methylnaltrexone Activity in Reversing Opioid-Induced Urinary Retention. Media Release: 10 Oct 2003. Available from URL: http://www.progenics.com

    Google Scholar 

  14. Progenics Pharmaceuticals Inc. Progenics initiates phase 2 clinical trial of methylnaltrexone to treat post-operative ileus. Media Release: 13 May 2003. Available from URL: http://www.progenics.com

    Google Scholar 

  15. Yuan C-S, Foss JF, O’Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA: the Journal of the American Medical Association 283: 367–372, 19 Jan 2000

    Article  CAS  Google Scholar 

  16. Progenics Pharmaceuticals Inc. Progenics announces results from methylnaltrexone phase 2 clinical trial in opioid-induced constipation. Media Release: 30 Apr 2003. Available from URL: http://www.progenics.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Methylnaltrexone. Drugs R D 7, 374–378 (2006). https://doi.org/10.2165/00126839-200607060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200607060-00006

Keywords

Search

Navigation